. 2021 Jun 3;29(12):7461–7469. doi: 10.1007/s00520-021-06321-7

Table 2.

Subgroup analyses of the association between diabetes and CIPN for study type, study quality, evaluation instrument and type of antineoplastic drug

Subgroup	No. of studies	No. of patients		OR (95% CI)	P heterogeneity	I² (%)	P interaction
Subgroup	No. of studies	DM + , n	DM − , n	OR (95% CI)	P heterogeneity	I² (%)	P interaction
Total	26	1605	7318	1.60 (1.38–1.85)	0.172	20.8
Type of study							0.88
Cohort	9	364	1371	1.44 (0.98–2.11)	0.107	39.1
Case–control	17	1241	5947	1.63 (1.39–1.91)	0.320	11.4
Study quality							0.60
High	23	1239	6775	1.50 (1.28–1.75)	0.304	11.5
Moderate	3	366	543	2.48 (1.65–3.72)	0.458	0
Evaluation instrument							0.87
Others	10	408	3394	1.50 (1.23–1.83)	0.284	17.3
NCI-CTCAE	16	1197	3924	1.72 (1.39–2.15)	0.179	24.3
Type of antineoplastic drug							0.81
Oxaliplatin only^a	8	284	1992	1.19 (0.86–1.65)	0.369	7.9
Taxane only^b	8	478	2353	1.47 (1.11–1.93)	0.114	39.8

^aEight studies reported the association between DM and oxaliplatin-induced neuropathy

^bEight studies reported the association between DM and taxane-induced neuropathy

DM diabetes mellitus; CIPN chemotherapy-induced peripheral neuropathy; OR odds ratio; CI confidence interval; NCI-CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Events